Last updated: February 28, 2026
Retatrutide Dosing Guide: 2mg, 4mg, 8mg, 12mg Protocol
This guide explains the recommended retatrutide dosing schedule, how to titrate from 2mg to 12mg, why gradual escalation improves tolerability, and how these doses compare with semaglutide and tirzepatide.
Retatrutide remains under clinical development and has not yet received full UK marketing authorisation. Read our full research disclaimer
Key Takeaways
Clinical efficacy data referenced: Jastreboff AM et al., The New England Journal of Medicine, June 26, 2023. View study
What Is the Recommended Retatrutide Dosing Schedule?
The recommended dosing schedule begins at 2mg weekly for four weeks, increases to 4mg weekly for four weeks, and then increases to 8mg weekly. Patients who tolerate 8mg well and require additional response may increase to 12mg weekly, which is the highest recommended dose.
Introduction Phase
Allows the gastrointestinal system to adjust to receptor activation. Reduces abrupt hormonal shifts and lowers early discontinuation rates.
Escalation Phase
Appetite suppression strengthens and caloric intake typically declines further. Continues metabolic adaptation without higher GI intensity.
Core Therapeutic Dose
The 8mg group achieved over 20% average weight reduction at 48 weeks. Activates the glucagon receptor more meaningfully, increasing energy expenditure.
Maximum Dose
Clinical trial data reported 24.2% mean weight reduction at 48 weeks. GI side effects increase compared with 8mg. Balance efficacy with tolerability.
Why Each Dosing Phase Matters
Each phase lasts four weeks to allow the body to adapt to triple receptor activation.
Starting at 2mg allows the gastrointestinal system to adjust to receptor activation. Retatrutide activates three distinct receptors:
- Glucagon-Like Peptide-1 (GLP-1) receptor
- Glucose-Dependent Insulinotropic Polypeptide (GIP) receptor
- Glucagon receptor
GLP-1 activation slows gastric emptying and reduces appetite. Rapid stimulation increases nausea risk. A 2mg introduction phase reduces abrupt hormonal shifts and lowers early discontinuation rates. Patients who skip the introductory phase often experience stronger nausea and vomiting.
The 4mg phase builds therapeutic momentum. At 4mg, appetite suppression strengthens and caloric intake typically declines further. This phase continues metabolic adaptation without introducing the higher gastrointestinal intensity associated with 8mg or 12mg.
Remaining at 4mg longer is acceptable for individuals who experience nausea.
8mg functions as the core therapeutic dose. In Phase 2 clinical trials, higher-dose groups demonstrated significantly greater mean weight reduction compared with placebo. The 8mg group achieved over 20% average weight reduction at 48 weeks in published research.
This dose activates the glucagon receptor more meaningfully, which increases energy expenditure. That mechanism explains why retatrutide often produces greater weight reduction than GLP-1-only medications.
12mg is the highest recommended dose. Patients who tolerate 8mg well and seek maximal response may increase to 12mg after at least four weeks at 8mg. Clinical trial data reported 24.2% mean weight reduction at 48 weeks at the highest studied dose.
However, gastrointestinal side effects increase at 12mg compared with 8mg. The decision to escalate should balance efficacy with tolerability.
Weekly Injection Instructions
Retatrutide is administered once weekly via subcutaneous injection. Consistent weekly timing improves hormonal stability.
- 1Store at 2-8°C.
Keep refrigerated until ready to use.
- 2Allow the pen to reach room temperature before injection.
Remove from fridge 30 minutes prior.
- 3Inject subcutaneously in the abdomen, thigh, or upper arm.
Pinch skin and insert at a 45-90° angle.
- 4Rotate injection sites weekly.
Prevents tissue damage from repeated injections.
- 5Dispose of needles in a sharps container.
Never reuse needles or dispose in household waste.
- Abdomen: Most common site, at least 5cm away from belly button
- Thigh: Front or outer thigh, mid-thigh area
- Upper Arm: Back of upper arm (may require assistance)
- Rotate Sites: Change injection location each week to prevent lipodystrophy
Storage Requirements
- Store between 2-8\u00B0C (36-46\u00B0F) in original packaging
- Keep away from light, do not freeze
Side Effects by Dose Level
Higher doses increase receptor activation intensity. Increased activation increases metabolic output and weight reduction, but also increases nausea probability.
Introduction Phase
Low GI Risk- Mild nausea in some individuals
- Reduced appetite
Escalation Phase
Mild GI Risk- Moderate appetite suppression
- Occasional nausea
Therapeutic Phase
Moderate GI Risk- Strong appetite suppression
- Noticeable reduction in food intake
- Increased likelihood of nausea
Maximum Phase
Higher GI Risk- Maximum appetite suppression
- Higher probability of gastrointestinal symptoms
Retatrutide Dosing Compared to Semaglutide and Tirzepatide
Retatrutide uses higher milligram dosing because it activates three receptors rather than one or two. The additional glucagon pathway increases energy expenditure, which contributes to greater weight reduction.
| Medication | Max Weekly Dose | Receptors Activated | Reported Mean Weight Reduction |
|---|---|---|---|
| Retatrutide | 12mg | GLP-1, GIP, Glucagon | 24.2% |
| Tirzepatide | 15mg | GLP-1, GIP | ~22.5% |
| Semaglutide | 2.4mg | GLP-1 only | ~14.9% |
Addressing Common Questions
Yes. Individuals who experience side effects at higher doses may remain at 4mg if adequate results occur.
No. Skipping titration increases gastrointestinal intolerance and early discontinuation.
No. Many individuals achieve meaningful results at 8mg.
Summary
The structured dosing protocol follows this progression:
Weeks 1-4
2mg weekly
Weeks 5-8
4mg weekly
Week 9 onward
8mg weekly
Optional escalation
12mg weekly
This approach balances efficacy and tolerability. Gradual increases reduce nausea while preserving weight reduction potential.